Cancer Immunotherapy with “Vascular-Immune” Crosstalk as Entry Point: Associated Mechanisms, Therapeutic Drugs and Nano-Delivery Systems
International Journal of Nanomedicine · 2024-07 · Volume 19 · 7383-7398
DOI: 10.2147/ijn.s467222 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2024-07. Verfasst von Zhijie Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, People's Republic of China. Hauptthemen laut MEDLINE: Neoplasms, Tumor Microenvironment, Immunotherapy, Neovascularization, Pathologic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, People's Republic of China.
Zitieren
APA
Jiang, Z., Fang, Z., Hong, D., & Wang, X. (2024). Cancer Immunotherapy with “Vascular-Immune” Crosstalk as Entry Point: Associated Mechanisms, Therapeutic Drugs and Nano-Delivery Systems. International Journal of Nanomedicine, Volume 19, 7383-7398. https://doi.org/10.2147/ijn.s467222
Vancouver
Jiang Z, Fang Z, Hong D, Wang X. Cancer Immunotherapy with “Vascular-Immune” Crosstalk as Entry Point: Associated Mechanisms, Therapeutic Drugs and Nano-Delivery Systems. International Journal of Nanomedicine. 2024;Volume 19:7383-7398. doi:10.2147/ijn.s467222
BibTeX
@article{Jiang2024,
author = {Jiang, Zhijie and Fang, Zhujun and Hong, Dongsheng and Wang, Xiaojuan},
title = {Cancer Immunotherapy with “Vascular-Immune” Crosstalk as Entry Point: Associated Mechanisms, Therapeutic Drugs and Nano-Delivery Systems},
journal = {International Journal of Nanomedicine},
year = {2024},
volume = {Volume 19},
pages = {7383--7398},
doi = {10.2147/ijn.s467222}
}
EUVIMED